<DOC>
	<DOCNO>NCT01738555</DOCNO>
	<brief_summary>This study open-label extension RFSP-AMDX-2010 study subject receive treatment amdoxovir ( 300 mg 500 mg twice daily ) 12 week benefit . This study examine safety efficacy investigational HIV drug , amdoxovir ( 300 mg 500 mg bid dose ; N = 30 ) combination zidovudine lopinavir/ritonavir 36 week . Subjects continue receive either amdoxovir 300 mg twice daily amdoxovir 500 mg twice daily , combination zidovudine 300 mg twice daily lopinavir/ritonavir ( 400 mg/100 mg twice daily ) additional 36 week .</brief_summary>
	<brief_title>A Safety Efficacy Study Amdoxovir HIV-1 Treatment-experienced Subjects</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Must complete Study RFSPAMDX2010 receive treatment amdoxovir ( 500 mg bid 300 mg bid ) 12 week entry study RFSPAMDX2012 . Must maintain â‰¥ 1.0 log10 copies/mL baseline Week 12 Study RFSPAMDX2010 . Must serious adverse experience since enrollment Study RFSPAMDX2010 , whether consider study drugrelated . Subjects require ongoing therapy nephrotoxic drug competitor renal excretion . Subjects require therapy hematologic , bone marrow suppressive cytotoxic agent . Subjects require medication highly dependent CYP3A clearance elevate plasma concentration associate lifethreatening adverse event . Known allergy/sensitivity hypersensitivity component study drug formulation . Women pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>amdoxovir</keyword>
	<keyword>zidovudine</keyword>
	<keyword>HIV</keyword>
	<keyword>HAART</keyword>
	<keyword>antiretroviral</keyword>
</DOC>